Dr. Roger Goldberg from Bay Area Retina Associates, Walnut Creek, CA discusses the latest data regarding the use of faricimab in diabetic macular edema and neovascular AMD.

We discuss various strategies for treatment pauses in management of neovascular AMD, differences between bevacizumab and aflibercept in patients who can be successfully paused, and intra ocular biomarkers that may identify eyes in which treatment may be successful paused with Dr. Akrit Sodhi, Associate Professor of Ophthalmology, Johns Hopkins University School of Medicine, Wilmer Eye Institute.

We review the current status of gene therapy for inherited retinal disorders, discussing preoperative evaluation, surgery, and follow up with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, University of Miami Miller School of Medicine, Bascom Palmer Eye Institute.

We discuss the use of a suprachoroidal delivery system for delivery of tryrosinase kinase inhibitor for the treatment of neovascular AMD with Dr. Thomas Ciulla, Chief Development Officer, Chief Medical Officer, Clearside Biomedical.

We discuss a phase 2/3 trial employing tarcocimab reformer for branch and central vein occlusion with Michael Singer, MD, Clinical Professor University of Texas San Antonio Health Sciences Center.

We discuss the  use of intravitreal avacincaptad peg for the treatment of geographic atrophy in two randomized trials, Gather 1 and Gather 2 with Dr. Arshad Khanani, Sierra Eye Associates, Reno Nevada and Associate Clinical Professor University of Nevada Reno.

We discuss the role that en-face optical coherence tomography (OCT) can play in understanding the evolution of intermediate AMD and geographic atrophy with Dr. Philip Rosenfeld, Professor of Ophthalmology, Bascom Palmer Eye Institute and the University of Miami Miller School of Medicine.

We review the 24 month results of the Derby and Oaks trials, with emphasis on the safety of pegcetcoplan with Caroline Baumal, MD, Professor of Ophthalmology Tufts University School of Medicine and the New England Eye Center.

Dr. Dennis Marcus, Clinical Professor of Ophthalmology, Medical College of Georgia at Augusta University discusses the value of ultra wide field imaging in assessing diabetic retinopathy worsening over time.

Dr. Michael Elman of Elman Retina Group, Baltimore, Maryland, presents 10 year data demonstrating that Preferential Hyperacuity Perimetry (the Foresee Device) is a valuable tool in early detection of neovascular AMD.